Epic Sciences

03.25.2019 Back to News Listings

Epic Sciences nets Myriad’s cancer president to serve as its CEO

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.

Sanders takes over for Murali Prahalad—who is stepping down after six years to pursue new opportunities, according to the company—though Prahalad will maintain a seat on Epic’s board of directors.

"Under Murali's leadership, the Epic team has made substantial progress in advancing our proprietary Functional Cell Profiling platform and successfully launching and obtaining Medicare coverage for the world's first predictive test for metastatic prostate cancer," Epic’s chairman, Gregory Lucier, said in a statement.

Read the full article on FierceBiotech.